New insights in diabetic autonomic neuropathy in children and adolescents

European Journal of Endocrinology

Volumn 161, Issue 6, 2009, Pages 811-818

  Verrotti, A ^a   Loiacono, G ^a   Mohn, A ^a   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDOSE REDUCTASE INHIBITOR; C PEPTIDE; GROWTH FACTOR; INSULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYOL; THIOCTIC ACID;

ADOLESCENT; ADOLESCENT HEALTH; ANHIDROSIS; AUTONOMIC NEUROPATHY; BIOACCUMULATION; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHILD; CHILD HEALTH; DIABETIC NEUROPATHY; DRY SKIN; ELECTROCARDIOGRAPHY; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HEART RATE; HEAT INTOLERANCE; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN SENSITIVITY; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; METABOLIC DISORDER; MICROANGIOPATHY; MOTOR DYSFUNCTION; OXIDATIVE STRESS; PATHOGENESIS; PRESSORECEPTOR REFLEX; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PUPIL DISEASE; REVIEW; SENSORY DYSFUNCTION; SIGNAL TRANSDUCTION; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; UPREGULATION; UROGENITAL TRACT DISEASE; VALSALVA MANEUVER;

ADOLESCENT; ANIMALS; CHILD; DIABETIC NEUROPATHIES; HUMANS;

EID: 72949120593     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0710     Document Type: Review

References (95)

1. Vinik AI & Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleveland Clinic Journal of Medicine 2001 68 928-944.
2. Freeman R. The peripheral nervous system and diabetes. In Joslin's Diabetes Mellitus. Eds G Weir, R Kahn & GL King Philadelphia, Lippincott 2002.
3. American Diabetes Association and American Academy of Neurology. Consensus Statement Report and recommendations of the San Antonio Conference on diabetic neuropathy. Diabetes 1988 11 592-597.
4. Vinik AI, Maser RE & Mitchell BD. Diabetic autonomic neuropathy. Diabetes Care 2003 26 1553-1579.
5. Pfeifer MA, Weinberg CR & Cook DL. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984 7 447-453.
6. Ziegler D, Dannehl K & Mühlen H. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabetic Medicine 1992 9 806-814.
7. Haslbeck M, Luft D & Neundörfer B. Diagnose, Therapie und Verlaufskontrolle der autonomen diabetischen Neuropathie. Evidenzbasierte Diabetes-Leitlinie DDG. Deutsche Diabetes-Gesellschaft 1. Auflage 2002.
8. Karavanaki K & Baum JD. Coexistence of impaired indices of autonomic neuropathy and diabetic nephropathy in a cohort of children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism 2003 16 79-90.
9. Wawryk AM, Bates DJ & Couper JJ. Power spectral analysis of heart rate variability in children and adolescents with IDDM. Diabetes Care 1997 20 1416-1421.
10. Donaghue KC, Fung AT, Fairchild JM, Howard NJ & Silink M. Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Diabetic Medicine 1996 13 65-71.
11. Verrotti A, Chiarelli F, Blasetti A & Morgese G. Autonomic neuropathy in diabetic children. Journal of Paediatrics and Child Health 1995 31 545-548.
12. Barkai L & Madacsy L. Cardiovascular autonomic dysfunction in diabetes mellitus. Archives of Disease in Childhood 1995 73 515-518.
13. Akinci A, Celiker A, Baykal E & Tezic T. Heart rate variability in diabetic children: sensitivity of the time and frequency-domain methods. Pediatric Cardiology 1993 14 140-146.
14. Scaramuzza A, Salvucci F & Leuzzi S. Cardiovascular autonomic testing in adolescents with type I (insulin-dependent) diabetes mellitus: an 18-month follow-up study. Clinical Science 1998 94 615-621.
15. Koepp P & Hamm H. Function of the autonomic nervous system in children and adolescents with insulin-dependent diabetes mellitus. Monatsschrift für Kinderheilkunde 1983 131 273-276.
16. Ziegler D, Gries FA, Spuler M & Lessmann F. Diabetic cardiovascular autonomic neuropathy multicenter study group: the epidemiology of diabetic neuropathy. Journal of Diabetes and its Complications 1992 6 49-57.
17. Solders G, Thalme B, Aguirre-Aquino M, Brandt L, Berg U & Persson A. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatrica 1997 86 361-366.
18. Suys BE, Huybrechts SJ & De Wolf D. QTc prolongation and QTc dispersion in children and adolescents with type 1 diabetes. Journal of Pediatrics 2002 141 59-63.
19. Vazeou A, Papadopoulou A & Papadimitriou A. Autonomic neuropathy and gastrointestinal motility disorders in children and adolescents with type 1 diabetes. Journal of Pediatric Gastroenterology and Nutrition 2004 38 61-65.
20. Toporowska-Kowalska E,Wasowska-Kròlikowska K, Szadkowska A, Mlynarski W & Bodalski J. Prevalence of EGG derangement in newly diagnosed type 1 diabetes in childhood. Journal of Pediatric Gastroenterology and Nutrition 2006 43 190-194.
21. Boysen A, Lewin MAG, Hecker W, Leichter HE & Uhlemann F. Autonomic function testing in children and adolescents with diabetes mellitus. Pediatric Diabetes 2007 8 261-264.
22. Dyck PJ & Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. Journal of Neuropathology and Experimental Neurology 1996 55 1181-1193.
23. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997 46 S50-S53.
24. Zochodne DW. Diabetic polyneuropathy: an update. Current Opinion in Neurology 2008 21 527-533.
25. Sundkvist G, Lind P, Bergstrom B, Lilja B & Rabinowe SL. Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients. Journal of Internal Medicine 1991 229 505-510.
26. Brussee V, Cunningham FA & Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004 53 1824-1830.
27. Singhal A, Cheng C & Sun H. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Research 1997 763 209-214.
28. Toth C, Brussee V & Zochodne DW. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 2006 49 1081-1088.
29. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd & Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008 131 3311-3334.
30. Xu QG, Li X-Q, Kotecha SA, Cheng C, Sun HS & Zochodne DW. Insulin as an in vivo growth factor. Experimental Neurology 2004 188 43-51.
31. Sugimoto K, Murakawa Y, Zhang W, Xu G & Sima AA. Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. Diabetes/Metabolism Research and Reviews 2000 16 354-363.
32. Toth C, Brussee V, Martinez JA, McDonald D, Cunningham FA & Zochodne DW. Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 2006 139 429-449.
33. Huang TJ, Price SA, Chilton L, Calcutt NA, Tomlinson DR & Verkhratsky A. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 2003 52 2129-2136.
34. Kamiya H, Zhang W & Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Annals of Neurology 2004 56 827-835.
35. Sima AA, Zhang W, Li ZG, Murakawa Y & Pierson CR. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 2004 53 1556-1563.
36. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P & Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003 52 536-541.
37. Zhang W, Kamiya H, Ekberg K, Wahren J & Sima AA. C peptide improves neuropathy in type 1 diabetic BB/Worrats. Diabetes/Metabolism Research and Reviews 2007 23 63-70.
38. Yan SF, D'Agati V & Schmidt AM. Receptor for advanced glycation endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Current Molecular Medicine 2007 7 699-710.
39. Fernyhough P, Smith DR, Schapansky J, Van Der Ploeg R, Gardiner NJ & Tweed CW. Activation of nuclear factor kappaB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. Journal of Neuroscience 2005 25 1682-1690.
40. Sugimoto K, Yasujima M & Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Current Pharmaceutical Design 2008 14 953-961.
41. Toth C, Rong LL & Yang C. RAGE and experimental diabetic neuropathy. Diabetes 2008 57 1002-1017.
42. Obrosova IG, Li F & Abatan OI. Role of poly (ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 2004 53 711-720.
43. Cheng C & Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003 52 2363-2371.
44. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R & Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. BioFactors 1999 10 157-167.
45. Schumer MP, Joyner SA & Pfeifer MA. Cardiovascular autonomic neuropathy testing in patients with diabetes. Diabetes Spectrum 1998 11 227-231.
46. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes/Metabolism Reviews 1994 339-383.
47. Weston PJ, James MA & Panerai RB. Abnormal baroreceptorcardiac reflex sensitivity is not detected by conventional tests of autonomic function in patients with insulindependent diabetes mellitus. Clinical Science 1996 91 59-64.
48. Weston PJ, James MA, Panerai RB, McNally PG, Potter JF & Thurston H. Evidence of defective cardiovascular regulation in insulin-dependent diabetic patients without clinical autonomic dysfunction. Diabetes Research and Clinical Practice 1998 42 141-148.
49. Lefrandt JD, Hoogenberg K, van Roon AM, Dullaart RP, Gans RO & Smit AJ. Baroreflex sensitivity is depressed in microalbuminuric type I diabetic patients at rest and during sympathetic manoeuvres. Diabetologia 1999 42 1345-1349.
50. Frattola A, Parati G & Gamba P. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 1997 40 1470-1475.
51. Ziegler D, Laude D, Akila F & Elghozi JL. Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clinical Autonomic Research 2001 11 369-376.
52. Dalla Pozza R, Bechtold S & Bonfig W. Impaired shortterm blood pressure regulation and autonomic dysbalance in children with type 1 diabetes mellitus. Diabetologia 2007 50 2417-2423.
53. Rosenga° rd-Bärlund M, Bernardi L, Fagerudd J, Mäntysaari M, Af Björkesten CG, Lindholm H, Forsblom C, Wadén J & Groop PH, FinnDiane Study Group. Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia 2009 52 1164-1172.
54. Krause M, Rüdiger H, Bald M, Näke A & Paditz E. Autonomic blood pressure control in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes 2009 10 255-263.
55. Javorka K, Javorková J, Petrásková M, Tonhajzerová I, Buchanec J & Chromá O. Heart rate variability and cardiovascular tests in young patients with diabetes mellitus type 1. Journal of Pediatric Endocrinology & Metabolism 1999 12 423-443.
56. Massin MM, Derkenne B, Tallsund M, Rocour-Brumioul D, Ernould C & Lebrethon MC. Cardiac autonomic dysfunction in diabetic children. Diabetes Care 1999 22 1845-1850.
57. Tanaka H, Hyllienmark L, Thulesius O, Brismar T, Ludvigsson J & Ericson MO. Autonomic function in children with type 1 diabetes mellitus. Diabetic Medicine 1998 15 402-411.
58. Riihimaa PH, Suominen K, Tolonen U, Jantti V, Knip M & Tapanainen P. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. Diabetes Care 2001 24 1087-1092.
59. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I & Gale EAM. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Diabetes Care 1999 22 495-502.
60. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA & Tamborlane WV. Impaired insulin action in puberty. New England Journal of Medicine 1986 315 215-219.
61. Holder M, Holl RW, Bartz J, Hercker W, Heinze E & Leichter HE. Influence of long-term glycemic control on the development of cardiac autonomic neuropathy in pediatric patients with type 1 diabetes. Diabetes Care 1997 20 1042-1043.
62. Karavanaki K, Davies AG, Morgan MH & Baum JD. Autonomic function in a cohort of children with diabetes. Journal of Pediatric Endocrinology & Metabolism 1997 10 599-607.
63. Riihimaa PH, Suominen K, Knip M, Tapanainen P & Tolonen U. Cardiovascular autonomic reactivity is decreased in adolescents with type 1 diabetes. Diabetic Medicine 2002 19 932-938.
64. Ewing DJ & Clarke BF. Diabetic autonomic neuropathy: a clinical viewpoint. In Diabetic Neuropathy, pp 66-88. Eds PJ Dyck, PK Thomas, AK Asbury, AI Weingrad & D Porte, Philadelphia: WB Saunders, 1987.
65. Ewing DJ, Campbell IW, Murray H, Neilson JM & Clarke BF. Immediate heart-rate response to standing: simple test for autonomic neuropathy in diabetes. BMJ 1978 1 145-147.
66. Ewing DJ, Martyn CN, Young RJ & Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985 8 491-498.
67. Agelink MW, Malessa R, Baumann B, Majewski T, Akila F, Zeit T & Ziegler D. Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. Clinical Autonomic Research 2001 11 99-108.
68. Ziegler D, Laux G & Dannehl K. Assessment of cardiovascular autonomic function: age related normal ranges and reproducibility of spectral analysis, vector analysis and standard test of heart rate variation and blood pressure responses. Diabetic Medicine 1992 9 166-175.
69. Nakagawa M, Takahashi N & Ooie T. Development of a new method for assessing the cardiac baroreflex: response to downward tilting in patients with diabetes mellitus. Heart 2001 86 643-648.
70. Kardos A, Watterich G, De Menezes R, Csanady M, Casadei B & Rudas L. Determinants of spontaneous baroreflex sensitivity in a healthy working population. Hypertension 2001 37 911-916.
71. Ruediger H & Bald M. Spontaneous baroreflex sensitivity in children and young adults calculated in the time and frequency domain. Autonomic Neuroscience 2001 93 71-78.
72. Tank J, Baevski RM & Fender A. Reference values of indices of spontaneous baroreceptor reflex sensitivity. American Journal of Hypertension 2000 13 268-275.
73. Kahn R. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy: autonomic nervous system testing. Diabetes Care 1992 15 1095-1103.
74. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. American Heart Journal 1982 19 399-411.
75. Schwartz PJ, Stramba-Badiale M, Segantini A, Austoni P, Bosi G & Giorgetti R. Prolongation of the QT interval and the sudden infant death syndrome. New England Journal of Medicine 1998 338 1709-1714.
76. De Bruyne MC, Hoes AW, Kors JA, Hofman A, Van Bemmel JH & Grobbee DE. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. European Heart Journal 1999 20 278-284.
77. Algra A, Tijssen J, Roelandt J, Pool J & Lubsen J. QTc prolongation measured by standard 12 lead electrocardiogram is an independent risk factor for sudden death. Circulation 1991 83 1888-1894.
78. Whitsel EA, Boyko EJ & Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care 2000 23 241-247.
79. Veglio M, Sivieri R, Chinaglia A, Scaglioni L & Cavallo-Perin P. QT interval prolongation and mortality in type 1 diabetic patients. Diabetes Care 2000 23 1981-1983.
80. Suys BE, Huybrechts SJA, De Wolf D, Op De Beeck L, Matthys D, Van Overmeire B, Du Caju MVL & Rooman RPA. QTc interval prolongation and QTc dispersion in children and adolescents with type 1 diabetes. Journal of Pediatrics 2002 141 59-63.
81. Martin CL, Albers J & Herman WH. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006 29 340-344.
82. Varkonyi T & Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes, Obesity & Metabolism 2008 10 99-108.
83. Tesfaye S, Chaturvedi N & Eaton SE. Vascular risk factors and diabetic neuropathy. New England Journal of Medicine 2005 352 341-350.
84. Kempler P, Tesfaye S & Chaturvedi N. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabetic Medicine 2002 19 900-909.
85. Ziegler D. Polyneuropathy in the diabetic patient update on pathogenesis and management. Nephrology, Dialysis, Transplantation 2004 19 2170-2175.
86. Chalk C, Benstead TJ & Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews 2007 4 CD004572.
87. Ziegler D, Nowak H & Kempler P. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine 2004 21 114-121.
88. Huang EA & Gitelman SE. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatric Diabetes 2008 9 69-73.
89. ZhangW, Kamiya H & Ekberg K. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes/Metabolism Research and Reviews 2007 23 63-70.
90. Ekberg K, Brismar T & Johansson BL. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007 30 71-76.
91. Cotter MA, Ekberg K, Wahren J & Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003 52 1812-1817.
92. Johansson BL, Berg K, Fernqvist-Forbes E, Kernell A, Odergren T & Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetic Medicine 2000 17 181-189.
93. Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M & Fink DJ. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Therapy 2005 12 1377-1384.
94. Lerner SM. Kidney and pancreas transplantation in type 1 diabetes mellitus. Mount Sinai Journal of Medicine 2008 75 372-384.
95. Roche E, Enseñat-Waser R, Reig JA, Jones J, León-Quinto T & Soria B. Therapeutic potential of stem cells in diabetes. Handbook of Experimental Pharmacology 2006 174 147-167.